Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
FT500 is a preparation of pluripotent cell line-derived natural-killer cells, which potentially increases T-cell recruitment to tumors, and may enhance anti-tumor immune response in combination with checkpoint inhibitors (Cancer Res 2018;78 (13 Suppl):Abstract nr 3576).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Atezolizumab + FT500||Atezolizumab FT500||0||1|
|FT500 + Nivolumab||FT500 Nivolumab||0||1|
|FT500 + Pembrolizumab||FT500 Pembrolizumab||0||1|